PMA PHARMACEUTICAL OUTCOMES PLANNING INCLUDES EFFORT TO ADDRESS MEASUREMENT OF "DISADVANTAGED CONDITIONS": SEPTEMBER MEETING WILL REVIEW ASSESSMENT TOOLS

Executive Summary

The Pharmaceutical Manufacturers Association is preparing to evaluate current performance measures that could be used as the foundation for a system to assess the quality of pharmaceutical care. Approximately 50-70 individuals suggested by PMA member companies are expected to participate in a Sept. 8-9 meeting in Washington, D.C. on the status of current measurement tools. The meeting will be the second this year held by the association to anticipate developments in the field of outcomes assessment and to try to ensure that the methods adopted in the future account for pharmaceutical treatments.